Marijuana Rescheduling & Schedule III: What It Means for Cannabis M&A
- Aug 25
- 9 min read
Marijuana Rescheduling to Schedule III: What DEA's New Position Means
Something remarkable happened in federal cannabis policy.
After decades in which marijuana’s Schedule I status helped define the federal government’s approach to cannabis, attorneys representing the Drug Enforcement Administration have now put a dramatically different position in writing:
“Marijuana can no longer remain in Schedule I.”
The statement appears in the government’s August 17, 2026 post-hearing brief in the federal marijuana rescheduling proceeding. DEA is asking Chief Administrative Law Judge Derek Julius to recommend moving marijuana from Schedule I to Schedule III under the Controlled Substances Act.
That does not mean broader marijuana rescheduling is complete.
It does not mean federal legalization has occurred.
And it certainly does not mean every challenge facing the regulated cannabis industry disappears.
But for cannabis business owners, investors and M&A participants, the government’s position deserves attention for a different reason:
Federal cannabis policy is moving, and a material change in federal treatment could eventually change the economics underlying cannabis businesses themselves.
For buyers and sellers, that raises a much more interesting question:
What Did the DEA Actually Say About Marijuana and Schedule III?
The federal marijuana rescheduling hearing ran from June 29 through July 15, 2026. On August 17, the government and parties opposing broader rescheduling submitted their post-hearing briefs. DEA’s formal position asks the administrative law judge to recommend moving marijuana to Schedule III.
The government’s argument is significant.
Under the Controlled Substances Act, Schedule I treatment depends on statutory criteria that include the absence of a currently accepted medical use and a lack of accepted safety for use under medical supervision.
The government now argues marijuana no longer satisfies two of the three requirements for Schedule I and that its abuse potential and dependency profile align more appropriately with Schedule III.
In other words, this isn’t simply an industry trade group arguing that federal cannabis policy should change.
The government itself is making the case.
That distinction matters.
The Federal Government’s View of Cannabis Is Changing
For years, one of the most obvious contradictions in American cannabis policy has been the enormous state-regulated medical cannabis industry existing alongside marijuana’s federal Schedule I classification.
The government’s current argument confronts that contradiction directly.
Its case relies in part on the Department of Health and Human Services’ determination that marijuana has a currently accepted medical use, including evidence concerning chronic pain, anorexia associated with certain medical conditions, and nausea and vomiting associated with chemotherapy.
The government also points to widespread medical use across the United States.
That doesn’t make cannabis risk-free.
It doesn’t settle every scientific or regulatory debate.
But it represents a substantial evolution in the federal government’s characterization of marijuana.
And this evolution didn’t begin on August 17.
Schedule III Has Already Arrived for Part of the Market
On April 23, 2026, the Department of Justice announced an unusual interim development.
DOJ placed FDA-approved products containing marijuana and marijuana products subject to qualifying state-issued medical marijuana licenses into Schedule III while simultaneously launching an expedited proceeding to consider broader rescheduling of marijuana.
That means federal cannabis policy has already begun moving away from the traditional all-Schedule-I framework.
The broader question now before the administrative process is whether marijuana should be transferred more generally from Schedule I to Schedule III.
For cannabis investors and operators, this matters because regulatory change rarely affects only regulation.
It can affect economics.
And economics affect M&A.
What Could Schedule III Mean for Cannabis M&A?
This is where Pac Garden believes the discussion becomes particularly interesting.
Most rescheduling coverage understandably focuses on Washington: the DEA, HHS, the Controlled Substances Act and federal politics.
Cannabis business owners have another question:
What does it mean for my company?
Potentially, quite a bit.
1. Cash Flow Could Become Even More Important
Cannabis valuations aren’t ultimately built on headlines.
They’re built on economics.
Revenue matters.
EBITDA matters.
But as we’ve discussed previously, free cash flow matters enormously because it tells investors how much cash a business actually generates after the expenses and investments required to operate it.
Any material change in federal tax treatment resulting from broader Schedule III implementation could therefore have implications for the cash-generation profile of affected cannabis operators.
The exact tax consequences should be evaluated by qualified tax professionals based on the final regulatory framework and each company’s circumstances.
But from an M&A perspective, the principle is straightforward:
If a business sustainably generates more after-tax cash, the economics of owning that business change.
And when economics change, valuation conversations can change with them.
2. Cannabis Business Valuations Could Change
This does not necessarily mean cannabis valuation multiples suddenly explode.
That’s an important distinction.
Suppose two businesses trade at exactly the same valuation multiple.
If one produces substantially more sustainable cash flow than the other, its enterprise value may nevertheless be higher.
That’s why sophisticated cannabis M&A analysis won’t simply ask:
“What multiple are dispensaries selling for?”
It should ask:
“What sustainable economic benefit is the buyer actually acquiring?”
Schedule III could potentially affect that calculation.
But it won’t make every cannabis business valuable.
A poorly operated company with weak margins, excessive debt, questionable compliance or an unsustainable lease remains a poorly operated company.
Federal reform doesn’t erase fundamentals.
3. Distressed Cannabis M&A Could Become More Interesting
California still has a substantial population of distressed cannabis businesses.
Some have valuable licenses.
Some occupy desirable real estate.
Some have excellent infrastructure.
Some have recognizable brands.
But their capital structures, taxes, operating losses, debt or other liabilities have made continued operation difficult.
That creates a fascinating M&A question.
What happens when the underlying regulatory and economic environment improves before all distressed operators disappear?
Strong operators may have opportunities to acquire:
licenses;
operating companies;
retail locations;
cultivation infrastructure;
manufacturing capacity;
distribution networks;
intellectual property;
real estate; and
strategic market positions.
Schedule III would not rescue every distressed cannabis company.
But it could influence how buyers evaluate what remains valuable inside those businesses.
4. Strategic Buyers May Revisit the Market
Cannabis M&A isn’t driven exclusively by private investors.
Existing operators are often the most logical buyers.
A retailer may want additional stores.
A cultivator may want retail distribution.
A manufacturer may want greater control of its supply chain.
A vertically integrated operator may want to enter another California market.
A multi-state operator may reconsider California exposure.
If federal regulatory risk continues to decline and business economics improve, some strategic buyers may reassess opportunities they previously considered unattractive.
That doesn’t guarantee another acquisition boom.
But it could gradually increase the universe of credible buyers.
And more credible buyers can improve price discovery.
5. Capital Could Become More Selective — Not Less
One mistake would be assuming federal reform means money suddenly pours indiscriminately into cannabis.
The opposite may ultimately be more interesting.
As an industry matures, capital often becomes more selective.
Investors begin distinguishing between:
strong and weak operators;
defensible and commoditized licenses;
profitable and unprofitable locations;
clean and problematic balance sheets;
sustainable and questionable EBITDA;
attractive and burdensome leases;
good and poor management teams.
That’s healthy.
A mature M&A market shouldn’t reward every company equally.
It should become better at identifying quality.
6. Limited-License Markets May Become Even More Important
California isn’t one homogeneous cannabis market.
Local jurisdictions have enormous influence over where cannabis businesses can operate and how many licenses may exist.
In some cities, cannabis licenses are relatively plentiful.
In others, local authorization is highly restricted.
Those limited-license jurisdictions can create meaningful barriers to entry.
If the federal environment becomes more favorable and additional capital or strategic buyers enter the market, scarce local operating rights may attract greater attention.
But scarcity alone doesn’t determine value.
Buyers still need to evaluate:
location;
population;
competition;
revenue;
liabilities;
profitability;
lease economics;
local taxes;
license standing;
operating history; and
growth potential.
A scarce license in a poor market is not automatically a great acquisition.
But a strong operation in a genuinely constrained market can be difficult to replicate.
7. Cannabis Due Diligence Will Still Matter
Perhaps more than ever.
Federal reform does not eliminate the need to understand what you’re buying.
Before acquiring a California cannabis company, buyers still need to investigate areas such as:
state licensing;
local authorization;
ownership;
financial statements;
tax exposure;
inventory;
track-and-trace records;
leases and real estate;
debt and liens;
litigation;
employees;
intellectual property; and
regulatory compliance.
That is why we recently published our Cannabis M&A Due Diligence Checklist.
A better macroeconomic environment cannot repair a bad acquisition.
What Schedule III Will NOT Fix
This may be the most important topic.
Schedule III is not a magic wand for California cannabis.
Even if broader marijuana rescheduling is ultimately completed, California operators would still face many of the industry’s structural challenges.
Those can include:
illicit-market competition;
state and local taxes;
intensive regulation;
price compression;
oversupply in certain categories;
expensive real estate;
difficult lease structures;
debt;
undercapitalization;
fragmented local regulations; and
operational inefficiency.
California itself continues to identify the illicit market as a major challenge. The state recently announced $227 million in funding aimed at combating illicit cannabis activity and protecting regulated markets and communities.
Federal reform may improve the playing field.
It does not replace good business execution.
The Bigger Cannabis M&A Thesis
This is why we believe the current rescheduling development is more interesting than another Washington headline.
The regulated cannabis industry has spent years operating under extraordinary constraints.
Capital became scarce.
Valuations compressed.
Businesses failed.
Assets changed hands.
Operators consolidated.
And sophisticated investors became much more demanding.
Now imagine federal policy becoming incrementally more rational at the same time.
The result may not be a return to the speculative cannabis markets of the past.
It could be something healthier:
an industry increasingly valued like an industry.
Cash flow matters.
Management matters.
Location matters.
License scarcity matters.
Real estate matters.
Compliance matters.
Balance sheets matter.
And transaction structure matters.
That’s what mature M&A markets look like.
Rescheduling Doesn’t Mean Legalization
This distinction is critical.
Moving marijuana from Schedule I to Schedule III would not constitute federal legalization.
Schedule III substances remain controlled under federal law.
Nor does DEA’s August 17 brief itself change marijuana’s broader federal scheduling.
It is a legal argument submitted in an ongoing administrative proceeding. And it overwhelming favors reform.
Chief Administrative Law Judge Derek Julius must now evaluate the record and prepare a recommended decision. The DEA Administrator ultimately holds final agency decision authority.
There is currently no fixed public date for Julius to issue that recommendation.
That uncertainty matters.
Business owners should make decisions based on the rules that actually exist rather than regulations they hope will exist later.
So, Is Schedule III Bullish for Cannabis M&A?
Potentially.
But perhaps not for the reason many people think.
The most interesting outcome isn’t necessarily that every cannabis company suddenly becomes worth more.
It’s that the industry could become more economically rational.
Better businesses may command stronger valuations.
Distressed assets may find better-capitalized owners.
Strategic buyers may return.
Cash-flow improvements may support transactions that previously didn’t pencil.
Limited licenses and quality locations may become increasingly important.
And sophisticated buyers may become more willing to commit capital when they can better quantify regulatory risk.
That is potentially good for cannabis M&A.
But it also means investors will have greater reason to distinguish good businesses from bad ones.
The Bottom Line
The DEA’s August 17 filing is noteworthy because the government’s position is now explicit:
It is arguing that marijuana no longer satisfies the requirements for Schedule I and should be transferred to Schedule III.
The final outcome remains unresolved.
But the direction deserves attention.
For California cannabis business owners, investors and acquirers, the biggest question isn’t simply whether marijuana moves from one federal schedule to another.
It’s what happens to cash flow, capital, valuations and M&A activity if the regulatory environment continues to normalize.
And that leads to perhaps the most important takeaway:
Rescheduling won’t rescue every cannabis business. It may make it easier to distinguish which businesses are worth acquiring, which are positioned to grow, and which assets belong in stronger hands.
That’s where cannabis M&A gets interesting.
Have Questions About Cannabis M&A?
Pac Garden provides strategic M&A advisory and commercial real estate services to cannabis business owners, operators, investors and buyers throughout California.
Whether you’re considering an acquisition, evaluating a potential sale, looking for strategic capital or trying to understand what your business may be worth, we’d be happy to start a conversation.
Disclaimer
The information provided in this article is for general educational and informational purposes only and should not be construed as legal, tax, accounting, financial, investment, regulatory or other professional advice. Cannabis laws, regulations, tax treatment and transaction structures are complex, subject to change and may vary by jurisdiction and circumstance. Readers should consult qualified legal counsel, tax advisors, accountants, regulatory professionals and other appropriate advisors regarding their specific circumstances before making business or investment decisions.
Pac Garden provides strategic mergers and acquisitions advisory and commercial real estate services. We routinely collaborate with attorneys, CPAs, regulatory professionals and other specialists in connection with transactions but do not provide legal, tax, accounting or investment advice.
FAQs
Q: Is marijuana currently Schedule III?
A: Not broadly. DOJ placed certain FDA-approved marijuana products and marijuana products subject to qualifying state medical-marijuana licenses into Schedule III in April 2026, while a separate administrative proceeding is considering broader transfer of marijuana from Schedule I to Schedule III.
Q: Did the DEA recommend moving marijuana to Schedule III?
A: In its August 17, 2026 post-hearing brief, the government asked Chief Administrative Law Judge Derek Julius to recommend transferring marijuana from Schedule I to Schedule III. That filing is an argument in the proceeding, not the final agency decision.
Q: Has marijuana rescheduling been finalized?
A: No. The post-hearing briefing phase has concluded, but the ALJ must issue a recommended decision and the DEA Administrator retains final decision authority.
Q: What would Schedule III mean for cannabis businesses?
A: The effects would depend on the final rule and its implementation. Potential implications could include changes affecting taxation, cash flow, investment decisions and business valuations. Businesses should obtain professional tax and legal advice regarding their specific circumstances.
Q: Would Schedule III federally legalize marijuana?
A: No. Schedule III substances remain controlled under federal law. Rescheduling and federal legalization are different legal concepts.
Q: Could Schedule III increase cannabis business valuations?
A: Potentially, but not automatically. Any improvement in sustainable cash flow, perceived regulatory risk or access to capital could influence valuation, while company-specific fundamentals such as profitability, licenses, location, debt, compliance and real estate would remain important.
Q: How could rescheduling affect cannabis M&A?
A: A more favorable federal environment could affect buyer interest, cash flow, valuations, distressed acquisitions and strategic consolidation. The ultimate effect will depend on the final regulatory framework and individual company fundamentals.
Comments